Elizabeth Tye
Nurse Practitioner · Albany, GANPI 1013228568
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,169 of the $78,159 with a category attached, or 82.1%. Novo Nordisk accounts for 91.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $28,256 and has fallen 62.4% since, to $10,612 in 2025. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $210.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$72K
- Amgen$2K
- Medtronic$2K
- AstraZeneca$341
- Bayer$316
- Abbott$299
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$64,16982%
- Travel & lodging$5,7317%
- Food & beverage$7,93910%
- Education$3210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 182 | $71,761 |
| Amgen(2 entities) | 44 | $2,013 |
| Medtronic | 30 | $1,647 |
| AstraZeneca | 7 | $341 |
| Bayer | 14 | $316 |
| Abbott | 11 | $299 |
| Lilly USA, LLC | 9 | $251 |
| Corcept Therapeutics | 6 | $229 |
| Astellas Pharma US Inc | 10 | $188 |
| Radius Health, Inc. | 7 | $120 |
| Dexcom, Inc. | 5 | $107 |
| Corium, LLC | 5 | $89 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $88 |
| Ascendis Pharma Endocrinology Inc | 1 | $80 |
| AbbVie | 4 | $70 |
| Exact Sciences | 4 | $69 |
| Ultragenyx Pharmaceutical Inc. | 3 | $69 |
| Kyowa Kirin, Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Rhythm Pharmaceuticals, Inc. | 1 | $31 |
| Tandem Diabetes Care, Inc. | 1 | $31 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Millicent US Inc | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Pfizer | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,159 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 314 | $400,966 |
| MounjaroTirzepatide | 163 | $194,894 |
| FarxigaDapagliflozin Propanediol | 131 | $106,251 |
| TrulicityDulaglutide | 58 | $72,796 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $65,167 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $62,134 |
| JardianceEmpagliflozin | 38 | $50,998 |
| KerendiaFinerenone | 49 | $47,861 |
| CreonLipase/Protease/Amylase | 20 | $44,140 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $41,132 |
| Humulin R U-500Insulin Regular, Human | 17 | $38,828 |
| InvokanaCanagliflozin | 25 | $35,491 |
| SynthroidLevothyroxine Sodium | 340 | $31,372 |
| RybelsusSemaglutide | 27 | $28,386 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $26,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $71,761 | $442,122394 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $251 | $275,519252 claims |
| AstraZenecaFarxiga | $341 | $106,251131 claims |
| AbbVieCreon, Synthroid, Linzess | $70 | $89,775379 claims |
| BayerKerendia | $316 | $47,86149 claims |
| PfizerGenotropin | $16 | $10,26012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Albany
- Mary HockmanAlbany$10K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Jessica AdkinsSavannah$226K
- Janice McAlisterAtlanta$221K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Luis PoloSavannah$70K
- Karen BauerDecatur$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.